Neurocrine Bioscienc
(NBIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,542 | -46,090 | 5,025 | 37,571 | -7,968 |
| Depreciation Amortization | 4,619 | 3,514 | 3,792 | 3,035 | 2,269 |
| Accounts receivable | -1,671 | 13,528 | -12,878 | 2,813 | -4,278 |
| Other Working Capital | 1,609 | 12,097 | -13,671 | -4,082 | -8,485 |
| Other Operating Activity | 8,845 | -12,656 | -17,562 | -40,035 | 68,405 |
| Operating Cash Flow | $-47,140 | $-29,607 | $-35,294 | $-698 | $49,943 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -103,411 | 5,953 | -33,793 | -4,823 | -54,948 |
| PPE Investments | -1,567 | -505 | -939 | -505 | 21 |
| Other Investing Activity | -388 | -108 | -29 | 1,796 | 223 |
| Investing Cash Flow | $-105,366 | $5,340 | $-34,761 | $-3,532 | $-54,704 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 138,731 | 5,302 | 83,702 | 286 | 21,483 |
| Financing Cash Flow | $138,731 | $5,302 | $83,702 | $286 | $21,483 |
| Beginning Cash Position | 44,789 | 63,754 | 50,107 | 54,051 | 37,329 |
| End Cash Position | 31,014 | 44,789 | 63,754 | 50,107 | 54,051 |
| Net Cash Flow | $-13,775 | $-18,965 | $13,647 | $-3,944 | $16,722 |
| Free Cash Flow | |||||
| Operating Cash Flow | -47,140 | -29,607 | -35,294 | -698 | 49,943 |
| Capital Expenditure | -1,612 | -545 | -971 | -750 | -315 |
| Free Cash Flow | -48,752 | -30,152 | -36,265 | -1,448 | 49,628 |